In a patient with Parkinson's disease who experiences seizures, are seizures a typical feature and how should they be evaluated and managed?

Seizures in Parkinson's Disease

Seizures are NOT a typical feature of Parkinson's disease, but when they occur, they represent a significant red flag requiring immediate investigation for underlying causes—particularly pyridoxine (vitamin B6) deficiency, structural brain lesions, or other seizure-provoking comorbidities.

Are Seizures Typical in Parkinson's Disease?

Seizures are distinctly uncommon in idiopathic Parkinson's disease (PD). However, when PD patients do develop seizures, they face a paradoxically higher risk of status epilepticus compared to epilepsy patients without PD (61.3% vs 11.7%, p<0.001) 1. This suggests that basal ganglia dysfunction in PD may impair seizure termination mechanisms once seizures begin.

The overall incidence of epileptic seizures in PD patients is approximately 266.7 per 100,000 person-years, representing a 2.37-fold increased risk compared to age-matched controls 2. The adjusted odds ratio for developing seizures in PD is 1.68, and this risk escalates dramatically in patients with comorbid brain disorders (OR 12.36) or multiple seizure-provoking comorbidities (OR 13.24) 2.

Critical Evaluation Priorities

When a PD patient presents with new-onset seizures, you must systematically evaluate:

1. Pyridoxine (Vitamin B6) Deficiency - Check This First

• This is a treatable and often overlooked cause specific to PD patients 3
• High-dose dopaminergic therapy increases pyridoxine metabolism
• PD-related gastrointestinal dysfunction impairs B6 absorption
• Dietary insufficiency is common due to depression and dysphagia
• Pyridoxine deficiency disrupts GABAergic neurotransmission, lowering seizure threshold
• Measure serum pyridoxine levels in all PD patients with new seizures

2. Structural Brain Pathology

• Obtain brain MRI to exclude:
  • Intracerebral hemorrhage
  • Ischemic stroke
  • Brain tumors or masses
  • Progressive neurodegenerative changes beyond typical PD

3. Metabolic and Toxic Causes

• Hypoglycemia
• Hyponatremia
• Hypoxia
• Drug toxicity or interactions
• Dopaminergic medication adjustments (recent dose escalations)

4. Non-Motor Seizures - A Diagnostic Pitfall

• PD patients may experience focal non-motor seizures with altered awareness that mimic non-motor symptoms of PD 4
• Acute episodes of cognitive changes, behavioral alterations, or fluctuating alertness warrant EEG evaluation
• These seizures are frequently misattributed to PD progression, causing diagnostic delays
• Standard EEG should be performed when episodic cognitive or behavioral changes occur

5. Systemic or CNS Infection

• Rule out meningitis, encephalitis, or systemic sepsis

Management Approach

If Seizures Are Active or Status Epilepticus:

Follow standard status epilepticus protocols 5:

1. First-line: Benzodiazepines (lorazepam or diazepam)

2. Second-line (if seizures persist after optimal benzodiazepine dosing):

   • Fosphenytoin, levetiracetam, or valproate may be used with similar efficacy 5
   • The 2024 ACEP guidelines (Level A recommendation) confirm these three agents have equivalent effectiveness
   • Levetiracetam may be preferred in PD patients due to:
     • Fewer drug interactions with dopaminergic medications
     • No hypotension risk (unlike phenytoin/fosphenytoin)
     • Minimal cognitive side effects
     • Dose: 30-50 mg/kg IV load at 100 mg/min

3. For refractory status epilepticus:

   • Valproate 20-30 mg/kg at 40 mg/min 6
   • Consider propofol or barbiturates for super-refractory cases 6

If Pyridoxine Deficiency Is Identified:

• Immediate pyridoxine supplementation (typical doses 50-200 mg daily, though specific dosing should be guided by deficiency severity)
• Monitor for seizure resolution
• Address underlying causes: optimize nutrition, manage GI symptoms, review medication interactions

Long-Term Seizure Management:

• Initiate appropriate anti-seizure medication based on seizure type
• Levetiracetam remains an excellent choice for chronic management in PD due to favorable side effect profile
• Avoid medications that worsen parkinsonism (e.g., valproate can occasionally worsen tremor)
• Continue routine pyridoxine monitoring in patients on high-dose dopaminergic therapy

Common Pitfalls to Avoid

1. Assuming cognitive/behavioral changes are "just PD" - Always consider non-motor seizures and obtain EEG when episodes are acute or episodic 4

2. Missing pyridoxine deficiency - This is a PD-specific, reversible cause that requires high clinical suspicion 3

3. Underestimating status epilepticus risk - PD patients have a 5-fold higher rate of progressing to status epilepticus once seizures begin 1

4. Attributing seizures to PD itself - Idiopathic PD does not cause seizures; their presence mandates investigation for alternative or comorbid pathology 2

5. Delaying epilepsy workup - The heterogeneous non-motor symptoms of PD can obscure seizure recognition, but episodic symptoms warrant prompt EEG evaluation 4